Man Group PLC C4 Therapeutics, Inc. Transaction History

Man Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$5.3 - $11.0 $105,284 - $218,515	-19,865 Reduced 12.43%	139,900 $1.14 Million
Q4 2023 Feb 14, 2024	BUY	$1.18 - $6.03 $10,109 - $51,659	8,567 Added 5.67%	159,765 $902,000
Q3 2023 Nov 14, 2023	BUY	$1.81 - $3.89 $148,177 - $318,458	81,866 Added 118.08%	151,198 $281,000
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $80,291 - $110,072	29,197 Added 72.75%	69,332 $190,000
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $124,418 - $362,017	40,135 New	40,135 $126,000
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $188,771 - $300,981	-6,423 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $35,910 - $50,500	1,000 Added 18.44%	6,423 $287,000
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $164,804 - $228,742	5,423 New	5,423 $205,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.